The New England journal of medicine · 2007 · Clinical trial · PMID 18057338
Explore the library
Insufficient evidenceGHRH analog
Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing hormone analog. Egrifta products have an FDA-approved indication involving excess abdominal fat in adults with HIV-associated lipodystrophy.
Also indexed as: Egrifta · TH9507
A clear starting point
Tesamorelin is a synthetic growth hormone-releasing hormone analog. Egrifta products have an FDA-approved indication involving excess abdominal fat in adults with HIV-associated lipodystrophy.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
GHRH / GH–IGF-1
Tesamorelin is a synthetic growth hormone-releasing hormone analog. Egrifta products have an FDA-approved indication involving excess abdominal fat in adults with HIV-associated lipodystrophy.
- Targets & processes
- GHRH / GH–IGF-1
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Visceral adipose tissue in adults with HIV-associated lipodystrophy.
What this does not establish
The approved indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not a general weight-loss drug; long-term cardiovascular safety is not established.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Contraindicated in pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis or hypersensitivity. Risks include elevated IGF-1, glucose intolerance and fluid retention.
Contraindications & cautions
Not an exhaustive contraindication review. Contraindicated in pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis or hypersensitivity. Risks include elevated IGF-1, glucose intolerance and fluid retention.
Medication & supplement interactions
Interaction information is incomplete. Contraindicated in pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis or hypersensitivity. Risks include elevated IGF-1, glucose intolerance and fluid retention.
Regulatory status · United States
FDA-approved product · narrow indication. Egrifta products are approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, not for general weight management.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.